Skip to content

Sildenafil Citrate

FDA-approved product (tablet, oral), marketed as Liqrev, Revatio, Sildenafil Citrate and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Sildenafil Citrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Connective tissue disease
  • Erectile dysfunction
  • Idiopathic and/or familial pulmonary arterial hypertension
  • Impotence
  • Pulmonary arterial hypertension
  • Pulmonary hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Drugs used in erectile dysfunction
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae39.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sildenafil Citrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension

    NCT07713914 · start 2026-07-22

    Registered record
    Registry ID
    NCT07713914
    Conditions
    Pulmonary Arterial Hypertension (PAH)
    Interventions
    Prostacyclin Pathway Agent; Sildenafil Dose Optimization
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-07-22
    Completion
    2028-12-31
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Arterial Hypertension (PAH)
    InterventionProstacyclin Pathway Agent; Sildenafil Dose Optimization
    PhasePhase 4
    Registry statusRecruiting
  • Vaginal Sildenafil for Primary Dysmenorrhea

    NCT07508358 · start 2026-05

    Registered record
    Registry ID
    NCT07508358
    Conditions
    Dysmenorrhea; Menstrual Pain
    Interventions
    Sildenafil citrate vaginal suppository; Placebo vaginal suppository
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-05
    Completion
    2027-10
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDysmenorrhea; Menstrual Pain
    InterventionSildenafil citrate vaginal suppository; Placebo vaginal suppository
    PhasePhase 1
    Registry statusNot yet recruiting
  • Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)

    NCT07462260 · start 2025-08-01

    Registered record
    Registry ID
    NCT07462260
    Conditions
    Pulmonary Hypertension; Rheumatic Valvular Heart Disease
    Interventions
    Sildenafil 25 MG; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2025-08-01
    Completion
    2026-06
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Hypertension; Rheumatic Valvular Heart Disease
    InterventionSildenafil 25 MG; Placebo
    PhasePhase 2 / Phase 3
    Registry statusRecruiting
  • Sildenafil 100 mg Tablets Relative to Viagra 100 mg Tablets

    NCT06289881 · start 2025-02-04

    Registered record
    Registry ID
    NCT06289881
    Conditions
    Healthy Subjects
    Interventions
    Sildenafill-Test product; Sildenafill-Reference product
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2025-02-04
    Completion
    2025-03-25
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionSildenafill-Test product; Sildenafill-Reference product
    PhasePhase 1
    Registry statusUnknown
  • Endovenous Sildenafil Early Management in Newborns Pulmonary Hypertension

    NCT04912726 · start 2025-01-01

    Registered record
    Registry ID
    NCT04912726
    Conditions
    Hypertension, Pulmonary
    Interventions
    Sildenafil Injectable Product
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2025-01-01
    Completion
    2026-12-30
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pulmonary
    InterventionSildenafil Injectable Product
    PhaseNot applicable
    Registry statusWithdrawn
  • Study to Compare the Effects of Viagra® Vs Hezkue® in Healthy Fasted Male Participants.

    NCT06782659 · start 2025-01

    Registered record
    Registry ID
    NCT06782659
    Conditions
    Erectile Dysfunction
    Interventions
    ASP-001; Viagra; ASP-001
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2025-01
    Completion
    2025-03
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction
    InterventionASP-001; Viagra; ASP-001
    PhasePhase 1
    Registry statusNot yet recruiting
  • Effects of Low-intensity Shockwave Therapy Versus Kegel Exercises on Arteriogenic Erectile Dysfunction in DM Patients

    NCT06058832 · start 2024-01-05

    Registered record
    Registry ID
    NCT06058832
    Conditions
    Sexual Dysfunction; Shock Wave
    Interventions
    Low-intensity Shockwave Therapy; Kegel Exercises
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-01-05
    Completion
    2024-09-06
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSexual Dysfunction; Shock Wave
    InterventionLow-intensity Shockwave Therapy; Kegel Exercises
    PhaseNot applicable
    Registry statusCompleted
  • Efficacy of Phosphodiesterase-type 5 Inhibitors in Patients With Univentricular Congenital Heart Disease

    NCT03997097 · start 2023-06-01

    Registered record
    Registry ID
    NCT03997097
    Conditions
    Single-ventricle; Pulmonary Hypertension; Univentricular Heart
    Interventions
    Sildenafil; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2023-06-01
    Completion
    2028-06-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSingle-ventricle; Pulmonary Hypertension; Univentricular Heart
    InterventionSildenafil; Placebos
    PhasePhase 3
    Registry statusWithdrawn
  • Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension

    NCT04039464 · start 2022-08-01

    Registered record
    Registry ID
    NCT04039464
    Conditions
    Pediatric Pulmonary Hypertension
    Interventions
    Mono-Therapy with Sildenafil; Duo-Therapy with Sildenafil + Bosentan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-08-01
    Completion
    2025-12-31
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric Pulmonary Hypertension
    InterventionMono-Therapy with Sildenafil; Duo-Therapy with Sildenafil + Bosentan
    PhasePhase 3
    Registry statusCompleted
  • Combined On-demand Sildenafil Citrate and Tramadol Hydrochloride for Treatment of Premature Ejaculation

    NCT05183334 · start 2021-12-30

    Registered record
    Registry ID
    NCT05183334
    Conditions
    Premature Ejaculation
    Interventions
    Sildenafil 50 mg; Placebo; Tramadol Hydrochloride 100 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-12-30
    Completion
    2022-12-25
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPremature Ejaculation
    InterventionSildenafil 50 mg; Placebo; Tramadol Hydrochloride 100 MG
    PhasePhase 4
    Registry statusUnknown
  • Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder

    NCT04948151 · start 2021-06-28

    Registered record
    Registry ID
    NCT04948151
    Conditions
    Female Sexual Arousal Disorder
    Interventions
    Sildenafil; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-06-28
    Completion
    2021-12-15
    Enrolment
    440

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFemale Sexual Arousal Disorder
    InterventionSildenafil; Placebo
    PhasePhase 2
    Registry statusUnknown
  • Sildenafil to Repair Brain Injury Secondary to Birth Asphyxia

    NCT04169191 · start 2019-09-19

    Registered record
    Registry ID
    NCT04169191
    Conditions
    Birth Asphyxia
    Interventions
    Sildenafil Citrate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-09-19
    Completion
    2025-10-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBirth Asphyxia
    InterventionSildenafil Citrate
    PhasePhase 1
    Registry statusCompleted
  • Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial

    NCT03855332 · start 2019-07-11

    Registered record
    Registry ID
    NCT03855332
    Conditions
    Small Vessel Cerebrovascular Disease
    Interventions
    Sildenafil; Cilostazol; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-07-11
    Completion
    2023-01-06
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Vessel Cerebrovascular Disease
    InterventionSildenafil; Cilostazol; Placebo
    PhasePhase 2
    Registry statusCompleted
  • Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)

    NCT04481789 · start 2018-10-17

    Registered record
    Registry ID
    NCT04481789
    Conditions
    Healthy Adult Subjects
    Interventions
    MT-1186; Rosuvastatin; Sildenafil; Furosemide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-10-17
    Completion
    2019-01-08
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Adult Subjects
    InterventionMT-1186; Rosuvastatin; Sildenafil; Furosemide
    PhasePhase 1
    Registry statusCompleted
  • Non-invasive Measurement of Cerebrovascular Reactivity After Traumatic Brain Injury

    NCT02990078 · start 2016-12

    Registered record
    Registry ID
    NCT02990078
    Conditions
    TBI
    Interventions
    Sildenafil citrate; Functional Near Infared Spectroscopy; Hypercapnia Challenge
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2016-12
    Completion
    2022-09-30
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTBI
    InterventionSildenafil citrate; Functional Near Infared Spectroscopy; Hypercapnia Challenge
    PhaseNot recorded
    Registry statusTerminated